Plus Therapeutics (NASDAQ: PSTV) was recently highlighted in an article by Mary Caffrey in The American Journal of Managed Care (AJMC) — one of the leading peer-reviewed journals covering the intersection of clinical innovation, policy, and patient access.
The feature, titled “Can Radiotherapeutics and Early Detection Offer a Breakthrough for Rare CNS Cancer?”, explores how Plus Therapeutics and its subsidiary, CNSide Diagnostics, are developing complementary technologies to tackle one of oncology’s toughest challenges: leptomeningeal metastases (LM).
Tackling a Rare but Devastating Disease
Each year, an estimated 110,000 people in the United States are affected by leptomeningeal metastases, a rare and aggressive form of cancer that spreads to the membranes surrounding the brain and spinal cord.
Yet, as the AJMC article notes, treatment options remain limited, expensive, and largely palliative — highlighting a critical need for new, targeted, and measurable solutions.
In the interview, Marc Hedrick, M.D., President and CEO of Plus Therapeutics, discusses how the company’s rhenium-186 radiotherapeutic platform and CSF-based diagnostic technologies are designed to address this gap head-on.
“We’re working to deliver targeted radiation directly to the central nervous system through our REYOBIQ™ (rhenium [Re186] obisbemeda) nanoliposome technology — while using CNSide™ to help clinicians identify and monitor patients more precisely,” Dr. Hedrick explained.
“Together, these tools represent a new way of thinking about how we detect and treat CNS cancers.”
Bridging Therapeutics and Diagnostics
The AJMC article underscores how Plus Therapeutics’ two core innovations work in tandem:
-
REYOBIQ™ — a targeted radiotherapeutic being studied in the ReSPECT-LM clinical trial for leptomeningeal metastases and other CNS cancers.
-
CNSide™ — a cerebrospinal fluid (CSF) assay platform developed by CNSide Diagnostics, designed to detect and quantify tumor cells in the CSF.
Importantly, AJMC highlights the recent national coverage agreement with UnitedHealthcare, which broadens patient access to CNSide™ testing and reinforces payer confidence in the diagnostic platform’s clinical relevance.
Together, these advances form the foundation of a new, integrated approach to central nervous system oncology — one that pairs precision radiotherapeutics with real-time diagnostic insight.
Why AJMC’s Coverage Matters
AJMC’s recognition of Plus Therapeutics’ work represents an important moment in the evolution of radiopharmaceuticals for rare CNS cancers. The journal’s readership — which includes healthcare policymakers, oncologists, and payer decision-makers — reflects the growing cross-sector interest in how novel treatment paradigms are reimbursed and adopted into care pathways.
For patients and caregivers, this coverage helps raise awareness about a disease area that is often overlooked — and offers renewed hope that scientific innovation can translate into better access and outcomes.
Read the Full Article
The American Journal of Managed Care
Can Radiotherapeutics and Early Detection Offer a Breakthrough for Rare CNS Cancer?
By Mary Caffrey
Read the full article here
Learn more about:
-
Plus Therapeutics’ radiotherapeutic programs: https://plustherapeutics.com/radiotherapeutics
-
CNSide Diagnostics’ assay platform: https://cnside-dx.com/
-
ReSPECT clinical trials: https://www.respect-trials.com
Recent Comments